17 June 2024
Nuformix
plc
("Nuformix" or the "Company")
Patent
Update
Nuformix plc (LSE: NFX), a
pharmaceutical development company targeting unmet medical needs in
fibrosis and oncology via drug repurposing, is pleased to
announce the following patent
update:
NXP002
NXP002 is the Company's lead asset
and a potential novel inhaled treatment for Idiopathic Pulmonary
Fibrosis ("IPF") for which the Company holds multiple
patents:
·
NXP002 Substance
of Matter: Following grants in the
US and Japan, the European Patent Office formally issued a grant of
patent number 3837238 on 12 June 2024 covering the Company's
proprietary NXP002 drug forms being progressed by the Company as a
potential novel IPF treatment.
·
NXP002 Method of
Use: The US PTO issued a grant of
patent application 17/365,490 on 14 June 2024, covering use of the
Company's proprietary drug forms in the treatment of various
diseases including fibrotic lung diseases.
·
NXP002
Compositions for Treatment: Now in
national filing stages and proceeding through
examination.
NXP004
The Company's NXP004 programme
is focused on the
development of novel, proprietary,
cocrystal forms of olaparib, a drug currently marketed by
AstraZeneca, under the Lynparza® brand name. On 14 June 2024
the US Patent and Trademark Office ("PTO") has granted the Company
patent number 12012386 covering the lead cocrystals under
development, representing the first granted patent in this second
NXP004 cocrystal series.
Dr
Dan Gooding, Executive Director of Nuformix, said:
"I'm delighted we've received these multiple
grants of key patents underpinning both our NXP002 and NXP004
programmes. The European patent grant represents the last major
territory to confirm protection of the novel drug forms enabling
NXP002's development as a potential novel IPF treatment. Granting
of the method of use patent in the US further strengthens our IP
position for this programme. The US PTO's decision to grant the
patent protecting the NXP004 programme's lead cocrystals is also a
first, with other territories soon to follow. The granting of these
patents is very helpful and timely in progressing on-going
discussions with potential development partners."
Enquiries:
|
Nuformix plc
|
|
|
Dr Dan Gooding, Executive
Director
|
Via IFC Advisory
|
|
Stanford Capital Partners Limited
|
|
|
Tom Price / Patrick Claridge
(Corporate Finance)
|
+44 (0) 20 3650 3650
|
|
Bob Pountney (Corporate
Broking)
|
+44 (0) 20 3650 3652
|
|
IFC
Advisory Limited
|
|
|
Tim Metcalfe
Zach Cohen
|
+44 (0) 20 3934 6630
nuformix@investor-focus.co.uk
|
About Nuformix
Nuformix is a pharmaceutical
development company targeting unmet medical needs in fibrosis and
oncology via drug repurposing. The Company aims to use its
expertise in discovering, developing and patenting novel drug
forms, with improved physical properties, to develop new products
in new indications that are, importantly, differentiated from the
original (by way of dosage, delivery route or presentation), thus
creating new and attractive commercial opportunities. Nuformix has
a pipeline of preclinical assets with potential for significant
value and early licensing opportunities.